M&A Deal Summary |
|
---|---|
Date | 2017-08-01 |
Target | TriMark |
Sector | Distribution |
Buyer(s) | Centerbridge Partners |
Sellers(s) | Warburg Pincus |
Deal Type | Secondary Buyout |
Advisor(s) | Barclays Investment Bank Jefferies (Financial) Kirkland & Ellis (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Asset Manager |
---|---|
Founded | 2005 |
PE ASSETS | 38.0B USD |
Size | Mega |
Type | Sector Agnostic |
Centerbridge Partners is a mega-sized private equity firm focused primarily on distressed/special situations in North America and Europe. In addition to making control investments, Centerbridge also maintains funds for non-control credit investments. Centerbridge was formed in 2005 and is based in New York City.
DEAL STATS | # |
---|---|
Overall | 30 of 47 |
Sector (Distribution) | 1 of 1 |
Type (Secondary Buyout) | 18 of 27 |
State (Massachusetts) | 3 of 4 |
Country (United States) | 26 of 39 |
Year (2017) | 5 of 6 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-07-06 |
Precisely
Burlington, Massachusetts, United States Precisely is a provider of data integrity software. The Company provides accuracy, consistency, and context in data for 12,000 customers in more than 100 countries. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Precisely is based in Burlington, Massachusetts. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-09-01 |
Sompo Canopius
Zurich, Switzerland Sompo Canopius writes global specialty lines (re)insurance with close to $100bn total assets and one of the top three Japanese insurers. Sompo Canopius underwrites a diversified portfolio of business from its operations at Lloyd's and around the world. It has achieved significant growth since its foundation through a mix of organic expansion and acquisition and is one of the top 10 insurers in the Lloyd’s insurance market, writing premiums in excess of $2 billion. |
Buy | $952M |
Category | Private Equity Firm |
---|---|
Founded | 1966 |
PE ASSETS | 83.0B USD |
Size | Mega |
Type | Sector Agnostic |
Warburg Pincus is a mega-sized, global private equity firm focused on investment opportunities across North America, Asia, and Europe. Warburg will consider investing at various company stages, from early-stage opportunities to distressed situations. Warburg Pincus is organized by industry groups. Verticals include financial services, healthcare, technology, media & telecommunications, energy, consumer & industrial, and real estate. Within financial services, Warburg will consider asset/wealth managers, banks, exchanges, financial technology, insurance, transaction processing, private banking, and specialty/consumer finance. Within healthcare, specific areas of interest include medical devices, healthcare services, and biotech/pharmaceuticals. Within technology/media/communications, Warburg targets software, media/internet/information, financial technology, telecom, business services, and systems/semiconductors. Within energy, specific areas of interest include oil/gas exploration, power generation/transmission, and alternative energy. Warburg Pincus raised its first fund in 1966 and is based in New York City.
DEAL STATS | # |
---|---|
Overall | 149 of 251 |
Sector (Distribution) | 1 of 1 |
Type (Secondary Buyout) | 20 of 42 |
State (Massachusetts) | 5 of 7 |
Country (United States) | 90 of 137 |
Year (2017) | 11 of 17 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-08-01 |
Evidon
New York, New York, United States Evidon, Inc. is a technology company focused on simplifying the complex world of Digital Governance. Fulfilling this promise requires organisations to have a comprehensive approach to govern data collection across their websites, applications and ads while complying with global regulations. Evidon, Inc. was established in 2009 and is based in New York, New York. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-08-09 |
Melinta Therapeutics
New Haven, Connecticut, United States Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. |
Sell | - |